AU2012200253A1 - Human protein tyrosine phosphatase inhibitors and methods of use - Google Patents
Human protein tyrosine phosphatase inhibitors and methods of use Download PDFInfo
- Publication number
- AU2012200253A1 AU2012200253A1 AU2012200253A AU2012200253A AU2012200253A1 AU 2012200253 A1 AU2012200253 A1 AU 2012200253A1 AU 2012200253 A AU2012200253 A AU 2012200253A AU 2012200253 A AU2012200253 A AU 2012200253A AU 2012200253 A1 AU2012200253 A1 AU 2012200253A1
- Authority
- AU
- Australia
- Prior art keywords
- compound according
- chosen
- ethyl
- thiadiazol
- thiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 title description 4
- 108090000144 Human Proteins Proteins 0.000 title description 3
- 102000003839 Human Proteins Human genes 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 108
- 230000033115 angiogenesis Effects 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 230000001105 regulatory effect Effects 0.000 claims abstract description 14
- -1 [1,3,4]thiadiazol-2-yl unit Chemical group 0.000 claims description 99
- 210000001519 tissue Anatomy 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 20
- 230000017423 tissue regeneration Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 230000012010 growth Effects 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- BEHLMOQXOSLGHN-UHFFFAOYSA-N benzenamine sulfate Chemical compound OS(=O)(=O)NC1=CC=CC=C1 BEHLMOQXOSLGHN-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 12
- 230000000302 ischemic effect Effects 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 7
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 6
- 210000002027 skeletal muscle Anatomy 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- FKTZFMQOSAFOBX-AWEZNQCLSA-N [4-[(2s)-2-[[5-(2-methoxy-2-oxoethyl)-1,3,4-thiadiazol-2-yl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid Chemical compound S1C(CC(=O)OC)=NN=C1N[C@H](C=1N=C(SC=1)C=1SC=CC=1)CC1=CC=C(NS(O)(=O)=O)C=C1 FKTZFMQOSAFOBX-AWEZNQCLSA-N 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 229910052797 bismuth Inorganic materials 0.000 claims description 3
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- MMYLSMYTNAHPDC-IBGZPJMESA-N [4-[(2s)-2-[(5-benzyl-1,3,4-thiadiazol-2-yl)amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid Chemical compound C1=CC(NS(=O)(=O)O)=CC=C1C[C@@H](C=1N=C(SC=1)C=1SC=CC=1)NC(S1)=NN=C1CC1=CC=CC=C1 MMYLSMYTNAHPDC-IBGZPJMESA-N 0.000 claims description 2
- NHLYJKHQNOQFLU-NRFANRHFSA-N [4-[(2s)-2-[(5-phenyl-1,3,4-thiadiazol-2-yl)amino]-2-(2-phenyl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid Chemical compound C1=CC(NS(=O)(=O)O)=CC=C1C[C@@H](C=1N=C(SC=1)C=1C=CC=CC=1)NC1=NN=C(C=2C=CC=CC=2)S1 NHLYJKHQNOQFLU-NRFANRHFSA-N 0.000 claims description 2
- MPMODSGSSRZHDE-KRWDZBQOSA-N [4-[(2s)-2-[[5-[(2-methyl-1,3-thiazol-4-yl)methyl]-1,3,4-thiadiazol-2-yl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid Chemical compound S1C(C)=NC(CC=2SC(N[C@@H](CC=3C=CC(NS(O)(=O)=O)=CC=3)C=3N=C(SC=3)C=3SC=CC=3)=NN=2)=C1 MPMODSGSSRZHDE-KRWDZBQOSA-N 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 2
- 125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 claims 2
- 125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 claims 2
- 125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims 2
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 claims 2
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 2
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 2
- KCEKCKYZZHREFI-UHFFFAOYSA-N 3h-thiadiazol-2-amine Chemical compound NN1NC=CS1 KCEKCKYZZHREFI-UHFFFAOYSA-N 0.000 claims 1
- WHQMOESGPHNDNU-KRWDZBQOSA-N [4-[(2s)-2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-2-(4-phenyl-1,3-thiazol-2-yl)ethyl]phenyl]sulfamic acid Chemical compound S1C(C)=NN=C1N[C@H](C=1SC=C(N=1)C=1C=CC=CC=1)CC1=CC=C(NS(O)(=O)=O)C=C1 WHQMOESGPHNDNU-KRWDZBQOSA-N 0.000 claims 1
- MHMREPFVAYYGLG-HNNXBMFYSA-N [4-[(2s)-2-[(5-propyl-1,3,4-thiadiazol-2-yl)amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid Chemical compound S1C(CCC)=NN=C1N[C@H](C=1N=C(SC=1)C=1SC=CC=1)CC1=CC=C(NS(O)(=O)=O)C=C1 MHMREPFVAYYGLG-HNNXBMFYSA-N 0.000 claims 1
- AORKWSDWFBHZBX-QHCPKHFHSA-N [4-[(2s)-2-[[5-(naphthalen-1-ylmethyl)-1,3,4-thiadiazol-2-yl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid Chemical compound C1=CC(NS(=O)(=O)O)=CC=C1C[C@@H](C=1N=C(SC=1)C=1SC=CC=1)NC(S1)=NN=C1CC1=CC=CC2=CC=CC=C12 AORKWSDWFBHZBX-QHCPKHFHSA-N 0.000 claims 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 101000738772 Homo sapiens Receptor-type tyrosine-protein phosphatase beta Proteins 0.000 abstract description 15
- 239000003112 inhibitor Substances 0.000 abstract description 13
- 230000000670 limiting effect Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 11
- DTNHUDDLCVNQFM-UHFFFAOYSA-N tert-butyl n-[4-bromo-1-(4-nitrophenyl)-3-oxobutan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(C(=O)CBr)CC1=CC=C([N+]([O-])=O)C=C1 DTNHUDDLCVNQFM-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 206010053648 Vascular occlusion Diseases 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 208000021331 vascular occlusion disease Diseases 0.000 description 5
- YSCKJLZYVJETAF-RSAXXLAASA-N (1s)-2-(4-nitrophenyl)-1-(2-phenyl-1,3-thiazol-4-yl)ethanamine;hydrobromide Chemical compound Br.C([C@H](N)C=1N=C(SC=1)C=1C=CC=CC=1)C1=CC=C([N+]([O-])=O)C=C1 YSCKJLZYVJETAF-RSAXXLAASA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- DNAWLDKKRJSPPJ-UHFFFAOYSA-N tert-butyl N-[4-diazo-1-(4-nitrophenyl)-3-oxobutan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(C(=O)C=[N+]=[N-])CC1=CC=C([N+]([O-])=O)C=C1 DNAWLDKKRJSPPJ-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000008467 tissue growth Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- CBBVPEYJGLWZEO-INIZCTEOSA-N 4-[(1s)-1-isothiocyanato-2-(4-nitrophenyl)ethyl]-2-phenyl-1,3-thiazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C[C@H](N=C=S)C1=CSC(C=2C=CC=CC=2)=N1 CBBVPEYJGLWZEO-INIZCTEOSA-N 0.000 description 3
- KKAUKPMBERGBHC-KRWDZBQOSA-N 5-methyl-n-[(1s)-2-(4-nitrophenyl)-1-(2-phenyl-1,3-thiazol-4-yl)ethyl]-1,3,4-thiadiazol-2-amine Chemical compound S1C(C)=NN=C1N[C@H](C=1N=C(SC=1)C=1C=CC=CC=1)CC1=CC=C([N+]([O-])=O)C=C1 KKAUKPMBERGBHC-KRWDZBQOSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000004352 blood vessel remodeling Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 108091007231 endothelial receptors Proteins 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001023 pro-angiogenic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 101000808896 Caenorhabditis elegans Potential E3 ubiquitin-protein ligase ariadne-2 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- BNMPXZKWADCLTR-KRWDZBQOSA-N [4-[(2s)-2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-2-(2-phenyl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid Chemical compound S1C(C)=NN=C1N[C@H](C=1N=C(SC=1)C=1C=CC=CC=1)CC1=CC=C(NS(O)(=O)=O)C=C1 BNMPXZKWADCLTR-KRWDZBQOSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005596 alkyl carboxamido group Chemical group 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XBQADBXCNQPHHY-NSHDSACASA-N 33305-77-0 Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C([N+]([O-])=O)C=C1 XBQADBXCNQPHHY-NSHDSACASA-N 0.000 description 1
- ZNOLNAPJKOYTHY-UHFFFAOYSA-N 4-(4-(P-Chlorophenyl)-2,5,6-Trihydropyridino)-4'-Fluorobutyrophenone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(C=2C=CC(Cl)=CC=2)CC1 ZNOLNAPJKOYTHY-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DDODATHUUUXYAI-FQEVSTJZSA-N 5-[(3-methoxyphenyl)methyl]-n-[(1s)-2-(4-nitrophenyl)-1-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]-1,3,4-thiadiazol-2-amine Chemical compound COC1=CC=CC(CC=2SC(N[C@@H](CC=3C=CC(=CC=3)[N+]([O-])=O)C=3N=C(SC=3)C=3SC=CC=3)=NN=2)=C1 DDODATHUUUXYAI-FQEVSTJZSA-N 0.000 description 1
- 206010000358 Accelerated hypertension Diseases 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101100334009 Caenorhabditis elegans rib-2 gene Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000606537 Homo sapiens Receptor-type tyrosine-protein phosphatase delta Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 description 1
- 208000035901 Ischaemic ulcer Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 208000004535 Mesenteric Ischemia Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100039666 Receptor-type tyrosine-protein phosphatase delta Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 1
- QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical compound NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 229920006258 high performance thermoplastic Polymers 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- DMEKUKDWAIXWSL-UHFFFAOYSA-N n,n-dimethyl-7-nitro-9h-fluoren-2-amine Chemical compound [O-][N+](=O)C1=CC=C2C3=CC=C(N(C)C)C=C3CC2=C1 DMEKUKDWAIXWSL-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Case No. AU 2012200253 Abstract The present invention relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-) inhibitors thereby regulating angiogenesis. Such compounds are of the following formula wherein variables R and Z are as defined in the specification herein. The present invention further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-) inhibitors, and to methods for regulating angiogenesis. \S N
Description
AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicant(s): Warner Chilcott, LLC Invention Title: Human protein tyrosine phosphatase inhibitors and methods of use The following statement is a full description of this invention, including the best method for performing it known to me/us: la HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE FIELD The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-0) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-p) inhibitors, and to methods for regulating angiogenesis. BACKGROUND Angiogenesis, the sprouting of new blood vessels from the pre-existing vasculature, plays a crucial role in a wide range of physiological and pathological processes (Nguyen, L.L. et al., Int. Rev. Cytol., 204, 1-48, (2001)). Angiogenesis is a complex process, mediated by communication between the endothelial cells that line blood vessels and their surrounding environment. In the early stages of angiogenesis, tissue or tumor cells produce and secrete pro angiogenic growth factors in response to environmental stimuli such as hypoxia. These factors diffuse to nearby endothelial cells and stimulate receptors that lead to the production and secretion of proteases that degrade the surrounding extracellular matrix. The activated endothelial cells begin to migrate and proliferate into the surrounding tissue toward the source of these growth factors (Bussolino, F., Trends Biochem. Sci., 22, 251-256, (1997)). Endothelial cells then stop proliferating and differentiate into tubular structures, which is the first step in the formation of stable, mature blood vessels. Subsequently, periendothelial cells, such as pericytes and smooth muscle cells, are recruited to the newly formed vessel in a further step toward vessel maturation. Angiogenesis is regulated by a balance of naturally occurring pro- and anti-angiogenic factors. Vascular endothelial growth factor, fibroblast growth factor, and angiopoeitin represent a few of the many potential pro-angiogenic growth factors. These ligands bind to their respective receptor tyrosine kinases on the endothelial cell surface and transduce signals that promote cell migration and proliferation. Whereas niany regulatory factors have been identified, the molecular mechanisms of this process are still not fully understood.
2 There are many disease states driven by persistent unregulated or improperly regulated angiogenesis. In such disease states, unregulated or improperly regulated angiogenesis may either cause a particular disease or exacerbate an existing pathological condition. For example, ocular neovascularization has been implicated as the most common cause of blindness and underlies the pathology of approximately 20 eye diseases. In certain previously existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous humor, causing bleeding and blindness. Both the growth and metastasis of solid tumors are also angiogenesis dependent (Folkman et al., "Tumor Angiogenesis," Chapter 10, 206-32, in The Molecular Basis ofCancer, Mendelsohn et al., eds., W. B. Saunders, (1995)). It has been shown that tumors which enlarge to greater than 2 mm in diameter must obtain their own blood supply and do so by inducing the growth of new capillary blood vessels. After these new blood vessels become embedded in the tumor, they provide nutrients and growth factors essential for tumor growth as well as a means for tumor cells to enter the circulation and metastasize to distant sites, such as liver, lung or bone (Weidner, New Eng. J. Med., 324, 1, 1-8 (1991)). When used as drugs in tumor-bearing animals, natural inhibitors of angiogenesis may prevent the growth of small tumors (O'Reilly et al., Cell, 79, 315-28 (1994)). In some protocols, the application of such inhibitors leads to tumor regression and dormancy even after cessation of treatment (O'Reilly et al., Cell, 88, 277-85 (1997)). Moreover, supplying inhibitors of angiogenesis to certain tumors may potentiate their response to other therapeutic regimens (Teischer et al., Int. J. Cancer, 57, 920-25 (1994)). Although many disease states are driven by persistent unregulated or improperly regulated angiogenesis, some disease states could be treated by increased angiogenesis. Tissue growth and repair are biologic events wherein cellular proliferation and angiogenesis occur. Thus an important aspect of wound repair is the revascularization of damaged tissue by angiogenesis. Chronic, non-healing wounds are a major cause of prolonged morbidity in the aged human population. This is especially the case in bedridden or diabetic patients who develop severe, non-healing skin ulcers. In many of these cases, the delay in healing is a result of inadequate blood supply either as a result of continuous pressure or of vascular blockage. Poor capillary circulation due to small artery atherosclerosis or venous stasis contributes to the failure 3 to repair damaged tissue. Such tissues are often infected with microorganisms that proliferate unchallenged by the innate defense systems of the body which require well vascularized tissue to effectively eliminate pathogenic organisms. As a result, most therapeutic intervention centers on restoring blood flow to ischemic tissues thereby allowing nutrients and immunological factors access to the site of the wound. Atherosclerotic lesions in large vessels may cause tissue ischemia that could be ameliorated by modulating blood vessel growth to the affected tissue. For example, atherosclerotic lesions in the coronary arteries may cause angina and myocardial infarction that could be prevented if one could restore blood flow by stimulating the growth of collateral arteries. Similarly, atherosclerotic lesions in the large arteries that supply the legs may cause ischemia in the skeletal muscle that limits mobility and in some cases necessitates amputation, which may also be prevented by improving blood flow with angiogenic therapy. Other diseases such as diabetes and hypertension are characterized by a decrease in the number and density of small blood vessels such as arterioles and capillaries. These small blood vessels are important for the delivery of oxygen and nutrients. A decrease in the number and density of these vessels contributes to the adverse consequences of hypertension and diabetes including claudication, ischemic ulcers, accelerated hypertension, and renal failure. These common disorders and many other less common ailments, such as Burgers disease, could be ameliorated by increasing the number and density of small blood vessels using angiogenic therapy. It has been suggested that one means for regulating angiogenesis is to treat patients with a human protein tyrosine phosphatase beta (HPTP-@) inhibitor (Kruegar et al., EMBO J., 9, (1990)) and, therefore, to satisfy this need the compounds of the present disclosure have been prepared. SUMMARY OF THE DISCLOSURE The compounds of the present disclosure are a new class of compounds that can regulate angiogenesis in humans. The present disclosure further relates to pharmaceutical compositions and their pharmaceutically acceptable salts, and/or pharmaceutical compositions thereof comprising.
4 a) an effective amount of one or more compounds according to the present disclosure; and b) an excipient.. The present disclosures also relate to methods for controlling angiogenesis, and thereby providing a treatment for diseases affected by angiogenesis, said methods comprising administering to a human an effective amount of a compound according to the present disclosure. These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (0 C) unless otherwise specified. All documents cited are in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present disclosure. DETAILED DESCRIPTION OF THE DISCLOSURE In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings: By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the relevant active compound without causing clinically unacceptable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. Throughout the description and claims of this specification the word "comprise" and other forms of the word, such as "comprising" and "comprises," means including but not limited to, and is not intended to exclude, for example, other additives, components, integers, or steps. As used in the description and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a composition" includes mixtures of two or more such compositions. "Optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
5 Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that when a value is disclosed, then "less than or equal to" the value, "greater than or equal to the value," and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value "10" is disclosed, then "less than or equal to 10" as well as "greater than or equal to 10" is also disclosed. It is also understood that throughout the application data are provided in a number of different formats and that this data represent endpoints and starting points and ranges for any combination of the data points. For example, if a particular data point "10" and a particular data point "15" are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed. The term "organic unit" as described herein refers to groups or moieties that comprise one or more carbon atoms and which form a portion of one of the compounds or pharmaceutically acceptable salts thereof. For example, many of the substituent units referred to elsewhere herein are organic units. In order to effectively function in the context of their presence in the compounds and/or salts disclosed herein, the organic units should often have variable ranges of restricted size and/or molecular weight, so as to provide desired binding to the target enzymes, solubility, bioabsorption characteristics. For example, organic unit can have, for example, 1-26 carbon atoms, 1-18 carbon atoms, 1-12 carbon atoms, 1-8 carbon atoms, or 1-4 carbon atoms. Organic units often have hydrogen bound to at least some of the carbon atoms of the organic units, and can optionally contain the common heteroatoms found in substituted organic compounds, such as oxygen, nitrogen, sulfur, and the like, or inorganic atoms such as 6 halogens, phosphorus, and the like.. One example, of an organic radical that comprises no inorganic atoms is a 5, 6, 7, 8-tetrahydro-2-naphthyl radical. In some embodiments, an organic radical can contain 1-10 inorganic heteroatoms bound thereto or therein, including halogens, oxygen, sulfur, nitrogen, phosphorus, and the like. Examples of organic radicals include but are not limited to an alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, mono-substituted amino, di-substituted amino, acyloxy, cyano, carboxy, carboalkoxy, alkylcarboxamido, substituted alkylcarboxamido, dialkylcarboxamido, substituted dialkylcarboxamido, alkylsulfonyl, alkylsulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy, haloalkyl, haloalkoxy, aryl, substituted aryl, heteroaryl, heterocyclic, or substituted heterocyclic radicals, wherein the terms are defined elsewhere herein. A few non-limiting examples of organic radicals that include heteroatoms include alkoxy radicals, trifluoromethoxy radicals, acetoxy radicals, dimethylamino radicals and the like. Substituted and unsubstituted linear, branched, or cyclic alkyl units include the following non-limiting examples: methyl (CI), ethyl (C 2 ), n-propyl (C 3 ), iso-propyl (C 3 ), cyclopropyl (C 3 ), n-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), tert-butyl (C 4 ), cyclobutyl (C 4 ), cyclopentyl (C), cyclohexyl (C 6 ), and the like; whereas substituted linear, branched, or cyclic alkyl, non-limiting examples of which includes, hydroxymethyl (C 1 ), chloromethyl (CI), trifluoromethyl (CI), aminomethyl (CI), 1-chloroethyl (C2), 2-hydroxyethyl (C 2 ), 1,2-difluoroethyl (C 2 ), 2,2,2 trifluoroethyl (C 3 ), 3-carboxypropyl
(C
3 ), 2,3-dihydroxycyclobutyl
(C
4 ), and the like. Substituted and unsubstituted linear, branched, or cyclic alkenyl include, ethenyl (C2), 3 propenyl (C), I -propenyl (also 2-methylethenyl) (C3), isopropenyl (also 2-methylethen-2-yl) (C3), buten-4-yl (C4), and the like; substituted linear or branched alkenyl, non-limiting examples of which include, 2-chloroethenyl (also 2-chlorovinyl) (C2), 4-hydroxybuten- l-yl (C4), 7 hydroxy-7-methyloct-4-en-2-yl (C9), 7-hydroxy-7-methyloct-3,5-dien-2-y (C), and the like. Substituted and unsubstituted linear or branched alkynyl include, ethynyl (C2), prop-2 ynyl (also propargyl) (C), propyn-1-yl (C 3 ), and 2-methyl-hex-4-yn-1-yl (C7); substituted linear or branched alkynyl, non-limiting examples of which include, 5-hydroxy-5-methylhex-3-ynyl (C7), 6-hydroxy-6-methylhept-3-yn-2-yl (Cs), 5-hydroxy-5-ethylhept-3-ynyl (Cg), and the like. Substituted and unsubstituted "alkoxy" are used herein denotes a unit having the general formula -OR1 00 wherein R 00 is an alkyl, alkylenyl, or alkynyl unit as defined herein above, for example, methoxy, methoxymethyl, methoxymethyl.
7 Substituted and unsubstituted "haloalkyl" are used herein denotes an alkyl unit having a hydrogen atom substituted by one or more halogen atoms, for example, trifluoromethyl, 1,2 dicloroethyl, and 3,3,3-trifluoropropyl. The term "aryl" as used herein denotes cyclic organic units that comprise at least one benzene ring having a conjugated and aromatic six-membered ring, non-limiting examples of which include phenyl (C 6 ), naphthylen-1-yl (Cio), naphthylen-2-yl (Cio). Aryl rings can have one or more hydrogen atoms substituted by another organic or inorganic radical. Non-limiting examples of substituted aryl rings include: 4-fluorophenyl (C 6 ), 2-hydroxyphenyl (C 6 ), 3 methylphenyl (C 6 ), 2-amino-4-fluorophenyl
(C
6 ), 2-(NN-diethylamino)phenyl
(C
6 ), 2 cyanophenyl (C 6 ), 2,6-di-teri-butylphenyl
(C
6 ), 3-methoxyphenyl (C 6 ), 8-hydroxynaphthylen-2 yl (CIo), 4,5-dimethoxynaphthylen-1-yl (CIo), and 6-cyanonaphthylen-1-yl (CIO). The term "heteroaryl" denotes an organic unit comprising a five or six member conjugated and aromatic ring wherein at least one of the ring atoms is a heteroatom selected from nitrogen, oxygen, or sulfur.. The heteroaryl rings can comprise a single ring, for example, a ring having 5 or 6 atoms wherein at least one ring atom is a heteroatom not limited to nitrogen, oxygen, or sulfur, such as a pyridine ring, a furan ring, or thiofuran ring.. A "heteroaryl" can also be a fused multicyclic and heteroaromatic ring system having wherein at least one of the rings is an aromatic ring and at least one atom of the aromatic ring is a heteroatom including nitrogen, oxygen, or sulfur The following are non-limiting examples of heteroaryl rings according to the present disclosure: , ; and N The term "heterocyclic" denotes a ring system having from 3 to 10 atoms wherein at least one of the ring atoms is a heteroatom not limited to nitrogen, oxygen, or sulfur. The rings can be single rings, fused rings, or bicyclic rings. Non-limiting examples of heterocyclic rings include: H ;H ; and All of the aforementioned heteroaryl or heterocyclic rings can be optionally substituted with one or more substitutes for hydrogen as described herein further.
8 Throughout the description of the present disclosure the terms having the spelling "thiophene-2-yl and thiophene-3-yl" are used to describe the heteroaryl units having the respective formulae: Cs whereas in naming the compounds of the present disclosure, the chemical nomenclature for these moieties are typically spelled "thiophen-2-yl and thiophen-3-yl" respectively. Herein the terms "thiophene-2-yi and thiophene-3-yl" are used when describing these rings as units or moieties which make up the compounds of the present disclosure solely to make it unambiguous to the artisan of ordinary skill which rings are referred to herein. The following are non-limiting examples of units that can substitute for hydrogen atoms: i) Ci-Ciz linear, branched, or cyclic alkyl, alkenyl, and alkynyl; for example, methyl (CI), ethyl (C2), ethenyl (02), ethynyl (C2), n-propyl (03), iso-propyl (C 3 ), cyclopropyl (C3), 3-propenyl (C3), 1-propenyl (also 2-methylethenyl) (C 3 ), isopropenyl (also 2-methylethen-2-yl) (C3), prop-2-ynyl (also propargyl) (03), propyn- 1-yl (C3), n-butyl (C4), sec-butyl (C4), iso-butyl (C 4 ), tert-butyl (04), cyclobutyl (C4), buten-4-yl (C4), cyclopentyl (Cs), cyclohexyl (C6); ii) substituted or unsubstituted C6 or Cio aryl; for example, phenyl, naphthyl (also referred to herein as naphthylen-1-yl (Cio) or naphthylen-2-yl (Cio)); iii) substituted or unsubstituted CI-C9 heterocyclic rings; as described herein below; iv) substituted or unsubstituted CI-C9 heteroaryl rings; as described herein below; v) -(CR1 2 aR 2 b)2OR"; for example, -OH, -CH 2 OH, -OCH 3 , -CH 2 0CH 3 , OCH 2
CH
3 , -CH 2 0CH 2
CH
3 , -OCH 2
CH
2
CH
3 , and -CH 2 0CH 2
CH
2
CH
3 ; vi) -(CR1 2 aRI 2 b)C(O)R"I; for example, -COCH 3 , -CH 2
COCH
3 , -OCH 2
CH
3 , CH 2
COCH
2
CH
3 , -COCH 2
CH
2
CH
3 , and -CH2COCH 2
CH
2
CH
3 ; vii) -(CRuMaR1 2 b)zC(O)OR" ; for example, --CO2CH 3 , -CH 2 C0 2
CH
3 , C0 2
CH
2
CH
3 , -CH 2
CO
2
CH
2
CH
3 , -C02CH 2
CH
2
CH
3 , and
CH
2
CO
2
CH
2
CH
2
CH
3 ; viii) -(CRaR 12b) C(O)N(R 1 )2; for example, -CONH 2 , -CH 2
CONH
2 , CONHCH 3 , -CH 2 CONHCH3, -CON(CH 3
)
2 , and -CH 2
CON(CH
3
)
2
;
9 ix) -(CR 2 aR 2 )zN(R" 1)2; ; for example, -NH 2 , -CH 2
NH
2 , -NHCH 3 , -N(CH 3
)
2 , NH(CH 2
CH
3 ), -CH 2
NHCH
3 , -CH 2
N(CH
3
)
2 , and -CH 2
NH(CH
2 CH3); x) halogen; -F, -Cl, -Br, and -I; xi) -(CR 1 2 R 12 2 )zCN; xii) -(CR 2 aR1 2 b)zNO 2 ; xiii) -CHjXk; wherein X is halogen, j is from 0 to 2, j + k = 3; for example, CH 2 F, -CHF 2 , -CF 3 , -CC1 3 , or -CBr 3 ; xiv) -(CR' 2 aR1 2 SR"; -SH, -CH 2 SH, -SCH 3 , -CH 2
SCH
3 , -SC 6 Hs, and CH 2
SC
6 Hs; xv) -(CRG"RIb2)zSO 2 R"; -SO 2 H, -CH 2
SO
2 H, -SO 2
CH
3 , -CH 2
SO
2
CH
3 ,
SO
2
C
6 Hs, and -CH 2
SO
2
C
6 Hs; and xiii) -(CR 1aRI 2 b)zSO 3 R"I; for example, -SO 3 H, -CH 2
SO
3 H, -S0 3
CH
3 , CH 2
SO
3
CH
3 , -SO 3
C
6 Hs, and -CH 2
SO
3 C6H5; wherein each R1 3 is independently hydrogen, substituted or unsubstituted CI-C 4 linear, branched, or cyclic alkyl, phenyl, benzyl; or two R1 3 units can be taken together to form a ring comprising 3-7 atoms; Ri1a and R14b are each independently hydrogen or CI-C4 linear or branched alkyl; the index p is from 0 to 4. For the purposes of the present disclosure the terms "compound," "analog," and "composition of matter" stand equally well for the phenylsulfamic acids described herein, including all enantiomeric forms, diastereomeric forms, salts, and the like, and the terms "compound," "analog," and "composition of matter" are used interchangeably throughout the present specification. The present disclosure addresses a major unmet medical need, inter alia; providing compositions of effective human protein tyrosine phosphatase beta (HPTP-p) inhibitors; and thereby provide a means for regulating angiogenesis and blood vessel remodeling in disorders wherein angiogenesis is decreased or where tissue blood flow is insufficient or where increased blood flow would be'beneficial. This and other unmet medical needs are resolved by the human protein tyrosine phosphatase beta (HPTP-p) inhibitors of the present disclosure, which are capable of regulating angiogenesis and blood vessel remodeling and thereby serve as a means for treating diseases 10 which are caused by insufficient regulation of human protein tyrosine phosphatase beta (HPTP p). The compounds disclosed herein include all pharmaceutically acceptable salt forms, for example, salts of both basic groups, inter alia, amines, as well as salts of acidic groups, inter alia, sulfamic acids, and carboxylic acids. The following are non-limiting examples of anions that can form salts with basic groups: chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, citrate, and the like. The following are non limiting examples of cations that can form salts of acidic groups: sodium, lithium, potassium, calcium, magnesium, bismuth, and the like. R Units R is a unit chosen from: i) hydrogen; ii) substituted or unsubstituted phenyl; and iii) substituted or unsubstituted heteroaryl ring. One example of R relates to compounds wherein R is hydrogen, said compounds having the general formula: S 0 0 N HO' N H Z H wherein Z is further defined herein below. Another example of the compounds of Formula (I) includes compounds wherein R is phenyl or substituted phenyl, said compounds having the general formula: s RI* N HO N H Z H wherein R' 0 represents one or more optional replacements for hydrogen. The following are non-limiting examples of R' 0 units that can substitute for hydrogen atoms on a phenyl unit: 11 i) CI-C, 2 linear, branched, or cyclic alkyl, alkenyl, and alkynyl; for example, methyl (CI), ethyl (C 2 ), ethenyl (C 2 ), ethynyl (C 2 ), n-propyl (C 3 ), iso-propyl (C 3 ), cyclopropyl (C 3 ), 3-propenyl (C 3 ), 1-propenyl (also 2-methylethenyl) (C 3 ), isopropenyl (also 2-methylethen-2-yl) (C 3 ), prop-2-ynyl (also propargyl) (C 3 ), propyn-l -yl (C 3 ), n-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), terr-butyl (C 4 ), cyclobutyl (C 4 ), buten-4-yl (C 4 ), cyclopentyl (Cs), cyclohexyl (C 6 ); ii) substituted or unsubstituted C 6 or CIO aryl; for example, phenyl, naphthyl (also referred to herein as naphthylen-1-yl (CIo) or naphthylen-2-yl (CIo)); iii) substituted or unsubstituted Cj-Cg heterocyclic rings; as described herein below; iv) substituted or unsubstituted CrC- heteroaryl rings; as described herein below; v) -(CR"R2a 12b).OR"; for example, -OH, -CH 2 OH, -OCH 3 , -CH 2
OCH
3 , OCH 2 CH3, -CH 2
OCH
2
CH
3 , -OCH 2
CH
2
CH
3 , and -CH 2
OCH
2
CH
2
CH
3 ; vi) -(CR 1 2 R 12)zC(O)R" ; for example, -COCH 3 , -CH 2
COCH
3 , -OCH 2
CH
3 , CH 2
COCH
2
CH
3 , -COCH 2
CH
2
CH
3 , and -CH 2
COCH
2
CH
2
CH
3 ; vii) -(CR 1 2 aRI 2 b) 2 C(O)OR" ; for example, -CO 2
CH
3 , -CH 2
CO
2
CH
3 ,
CO
2
CH
2
CH
3 , -CH 2
CO
2
CH
2
CH
3 , -CO 2
CH
2
CH
2
CH
3 , and
CH
2
CO
2
CH
2
CH
2
CH
3 ; viii) -(CR1 2 aR1 2 b)zC(O)N(R")2; for example, -CONH 2 , -CH 2
CONH
2 , CONHCH 3 , -CH 2
CONHCH
3 , -CON(CH 3
)
2 , and -CH 2
CON(CH
3
)
2 ; ix) -(CR 2 aR4 2 I)7N(R" 1)2; ; for example, -NH 2 , -CH 2
NH
2 , -NHCH 3 , -N(CH 3
)
2 , NH(CH 2
CH
3 ), -CH 2
NHCH
3 , -CH 2
N(CH
3
)
2 , and -CH 2
NH(CH
2
CH
3 ); x) halogen; -F, -Cl, -Br, and -I; xi) -(CR 2 0Ri 2 b)zCN; xii) -(CRUaRI 2 b )NO 2 ; xiii) -CHjXk; wherein X is halogen, j is from 0 to 2, j + k = 3; for example, CH 2 F, -CHF 2 , -CF 3 , -CC1 3 , or -CBr 3 ; xiv) -(CR 2 aR12b) 2 SR"'; -SH; -CH 2 SH, -SCH 3 , -CH 2
SCH
3 , -SC 6 HS, and
CH
2
SC
6
H
5 ; xv) -(CR 2 aR 2 b)zSO 2 R"; -SO2H, -CH 2
SO
2 H, -SO 2
CH
3 , -CH- 2 S0 2
CH
3 , S0 2
C
6
H
5 , and -CH 2
SO
2
C
6 Hs; and 12 xiii) -(CR"R 2 b )SO 3 R"; for example, -SO 3 H, -CH 2
SO
3 H, -SO 3
CH
3 , CH 2
SO
3
CH
3 , -SO 3
C
6 Hs, and -CH 2
SO
3
C
6 Hs; wherein each R 13 is independently hydrogen, substituted or unsubstituted CI-C 4 linear, branched, or cyclic alkyl, phenyl, benzyl; or two R1 3 units can be taken together to form a ring comprising 3-7 atoms; R14a and RI 4 b are each independently hydrogen or CI-C 4 linear or branched alkyl; the index p is from 0 to 4. Another example of the compounds of Formula (I) includes compounds wherein R is a substituted or unsubstituted heteroaryl ring. For the purposes of the present disclosure the following are non-limiting examples of heteroaryl rings suitable as R units for the compounds of the present disclosure: 1,2,3,4-tetrazolyl; [1,2,3]triazolyl; imidazolyl; pyrrolyl; oxazolyl; isoxazolyl; (1,2,4]oxadiazolyl; [1,3,4]oxadiazolyl; furanyl; thiopheneyl; isothiazolyl; thiazolyl; [1,2,4]thiadiazolyl; and [1,3,4]thiadiazolyl. The heteroaryl units that comprise R units can be substituted by one or more units chosen from methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, cyclopropylmethyl, methoxy, ethoxy, n-propoxy, iso-propoxy, cyclopropoxy, n-butoxy, sec butoxy, iso-butoxy, tert-butoxy, cyclopropoxy, fluoro, chloro, fluoromethyl, difluoromethyl, and trifluoromethyl. An example of the compounds of Formula (I) includes compounds wherein R units include units having the formulae: s Another example of the compounds of Formula (I) includes compounds wherein R units include units having the formulae: A further example of the compounds of Formula (I) includes compounds wherein R units include units having the formulae: Z is a substituted or unsubstituted [1,3,4]thiadiazol-2-yl unit having the formula: 13
N
and R' is a substituent group that can be independently chosen from a wide variety of inorganic (hydrogen, hydroxyl, amino, halogen or the like) or organic substituent units, such as alkyls, cycloalkyls, heterocyclic, heteroaryls, and the like, wherein such substituent units can optionally have from I to 12 carbon atoms, or I to 10 carbon atoms, or I to six carbon atoms. In many aspects of the invention R' is chosen from: i) hydrogen; ii) substituted or unsubstituted C-C 6 linear, branched, or cyclic alkyl; iii) substituted or unsubstituted C 6 or CIO aryl; iv) -OR 4 ; v) -C(O)OR 5 ; vi) -COR 6 ; and vii) -NR 7
C(O)OR
8 ;
R
4 is hydrogen or substituted or unsubstituted CI-C 6 linear, branched, or cyclic alkyl; R 5 is C)-C 6 linear or branched alkyl, or benzyl; R 6 is Ci-C6 linear, branched, or cyclic alkyl, or phenyl; R 7 is hydrogen or methyl; Ra is Ci-C 6 linear or branched alkyl, or benzyl. One example of compounds according to Formula (I) includes an R' unit that is hydrogen thereby providing compounds having the general formula: s N H0,S, Nj - HN, HO HN Ys H N'N wherein R is defined herein above. Another example of compounds according to Formula (1) includes compounds wherein R' is substituted or unsubstituted Ci-C 6 linear, branched, or cyclic alkyl, non-limiting examples of which include R' units chosen from methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and cyclopropylmethyl. A further example of compounds according to Formula (I) includes compounds wherein R' is a substituted or unsubstituted C 6 or CIO aryl unit, i.e. phenyl, naphthylen-1-yl, and naphthylen-2-yl. Non-limiting examples of this aspect include phenyl, 2-fluorophenyl, 3- 14. fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2 isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl, 2-cyanophenyl, 3-cyanophenyl, 4 cyanophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2-aminophenyl, 2-(N methylamino)phenyl, 2-(N,N-dimethylamino)phenyl, 2-(N-ethylamino)phenyl, 2-(NN diethylamino)phenyl, 3-aminophenyl, 3-(N-methylamino)phenyl, 3-(NN-dimethylamino)phenyl, 3-(N-ethylamino)phenyl, 3-(N,N-diethylamino)phenyl, 4-aminophenyl, 4-(N methylamino)phenyl, 4-(N,N-dimethylamino)phenyl, 4-(N-ethylamino)phenyl, 4-(NN diethylamino)phenyl, naphthylen-1-yl, and naphthylen-2-yl A yet further example of compounds according to Formula (1) includes compounds wherein R' has the formula -NR 7 C(O)ORS; R7 is hydrogen and R 8 is chosen from methyl (CI), ethyl (C2), n-propyl (C 3 ), iso-propyl (C 3 ), and cyclopropyl (C 3 ). The Z units of the present disclosure can further comprise a linking unit L, which when present, serves to connect the [1,3,4]thiadiazol-2-yl unit to the R' unit. When the index x is equal to 0, the linking unit is absent. When the index x is equal to I the linking unit is present. L is a linking unit having the formula: -[C(R9aR9%)]-; wherein R 9 a and R 9 b are each independently hydrogen, CI-C 6 linear or branched alkyl, or phenyl and the index y is from I to 4. One example of L units includes units wherein R 9 a and Rb are each hydrogen and the index y is equal to 1, these units have the formula:
-CH
2 that is also referred to herein as methylene linking units. Another example of L units includes units wherein all R 9 a and R units are hydrogen and the index y is equal to 2, this unit has the formula:
-CH
2 CH2 and is also referred to herein as an ethylene linking unit. A described herein above the compounds of the present invention includes all pharmaceutically acceptable salt forms. A compound having the formula: 15 N. N 0 0N HO N / N H- Y >-CH' N-N can form salts, for example, a salt of the sulfonic acid: N NH, -S
NH
4 0 N > CH N N ;and S 2 0 N 20 2 sHN O0 N H YN/ CH3 N N The compounds can also exist in a zwitterionic form, for example: s N o N H S H H /- CH_ N-N ;or as a salt of a strong acid, for example: N HO NjerH V S H CI( H N//-CH 3 N The analogs (compounds) of the present disclosure are arranged into several categories to assist the formulator in applying a rational synthetic strategy for the preparation of analogs which are not expressly exampled herein. The arrangement into categories does not imply increased or decreased efficacy for any of the compositions of matter described herein.
16 The compounds of the present disclosure can be prepared using the procedure outlined herein below in steps (a) - (f) or by making modifications thereof which are known to those skilled in the art and by which can be accomplished without the need for undue experimentation. Step (a) 0 0 OH A2 N 2 SHN.. HN 02N4 Pr O2N Pr Pr = protecting group Step (b) 0 sHN, HN. 0 2 N Pr 0 2 N Pr Step (c) Br S 02N + H 2 N R ON 02N4 Pr 02N -' I{ 2 Br Step (d) N R 0 2 N 202N4~ C Step (e) S -R 0 > R N + .. NNI 2 q ";" NSRI-(L RN ' 0 2 N I NCS 0 2 N (L)-R N ( Step (f) 17 S S N N 0 2 ~ HN S YS~SN 02NR H O O O H (L);-R N N Scheme I herein below outlines the procedure for preparing the analogs of the present disclosure that is described in detail in Example 1. Scheme I 0 0 OH 0 2 N OH ' 0 2 N 2HNYO
H
3 C ThH 3 C CH 3 1 Reagents and conditions: (a)(i) (iso-butyl)OCOCl, Et 3 N, THF; 0 "C, 20 min. (ii) CH2N2; 0 0C to room temp for 3 hours. 0 12 N 2 Br 0 2 N Hy00 2 N ~ N~ S CH 3 O CH3
H
3 C 3
H
3 C C 3 1 2 Reagents and conditions: (b) 48% HBr, THF; 0 *C, 1.5 hr.
18 0 Br S N12 0 0 2 40 N1H 2 HBr 23 Reagents and-conditions:-(c)-CH3CN;eflux 2hr. 0 2 N 0 2 N NCS 3 4 Reagents and conditions: (d) thiophosgene, CaCO 3 , CCl 4 , H 2 0; tt, 18 hr. SS
NCS
0 2 N 0 2 N 4 5 Reagents and conditions: (e)(i) CH 3
C(O)NHNH
2 , EtOH; reflux, 2 hr. (ii) POCl 3 , rt 18 hr; 50 *C 2 hr. SS 0 2 N HO N N N 5 6 Reagents and conditions: (f) (i) H 2 :Pd/C, MeOH; (ii) S0 3 -pyridine, NH 4 0H.
19 EXAMPLE I (S)-4-(2-(5-methyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4 yl)ethyl)phenylsulfamic acid (6) Preparation of [3-diazo-1-(4-nitrobenzyl)-2-oxo-propyl]-carbamic acid tert-butyl ester (1): To a 0 *C solution of 2-(S)-tert-butoxycarbonylamino-3-(4-nitrophenyl)-propionic acid (1.20 g, 4.0 mmol) in THF (20 mL) is added dropwise triethylamine (0.61 mL, 4.4 mmol) followed by iso-butyl chloroformate (0.57 mL, 4.4 mmol). The reaction mixture is stirred at 0 *C for 20 min and filtered. The filtrate is treated with an ether solution of diazomethane (-16 mmol) at 0 *C. The reaction mixture is stirred at room temperature for 3 hours and concentrated. The residue is dissolved in EtOAc and washed successively with water and brine, dried (Na 2 SO4), filtered and concentrated in vacuo, The resulting residue is purified over silica (hexane/EtOAc 2:1) to afford 1.1 g (82% yield) of the desired product as a slightly yellow solid. 'H NMR (300 MHz, CDCl 3 ) 5 8.16 (d, J= 8.7 Hz, 2H), 7.39 (d, J 8.7 Hz, 2H), 5.39 (s, I H), 5.16 (d, J= 6.3 Hz, 1 H), 4.49 (s, IH), 3.25 (dd, J= 13.8 and 6.6, 1H), 3.06 (dd, J= 13.5 and 6.9 Hz, 1H), 1.41 (s, 9H). Preparation of [3-bromo-1-(4-nitro-benzyl)-2-oxo-propyl]-carbamic acid tert-butyl ester (2): To a 0 *C solution of [3-diazo-1-(4-nitrobenzyl)-2-oxo-propyl]-carbamic acid tert-butyl ester, 1, (0.350 g, 1.04 mmol) in THF (5 mL) is added dropwise 48% aq. HBr (0.14 mL, 1.25 mmol). The reaction mixture is stirred at 0 *C for 1.5 hours and quenched at 0 *C with sat.Na 2 CO3. The mixture is extracted with EtOAc (3x 25 mL) and the combined organic extracts are washed with brine, dried (Na 2 SO4), filtered and concentrated in vacuo to afford 0.400 g of the desired product which is used in the next step without further purification. 'H NMR (300 MHz, CDCl 3 ) 8 8.20 (d, J= 8.4 Hz, 2H), 7.39 (d, J= 8.4 Hz, 2H), 5.06 (d, J= 7.8 Hz, I H), 4.80 (q, J= 6.3 Hz, IH), 4.04 (s, 2H), 1.42 (s, 9H). Preparation of (S)-2-(4-nitrophenyl)-1 -(2-phenylthiazol-4-yl)ethanamine hydrobromide salt (3): A mixture of [3-bromo-1-(4-nitro-benzyl)-2-oxo-propyl]-carbamic acid -tert-butyl ester, 2, (1.62 g, 4.17 mmol) and benzothioamide (0.630 g, 4.59 mmol), in CH 3 CN (5 mL) is refluxed for 24 hours. The reaction mixture is cooled to room temperature and diethyl ether (50 20 mL) is added to the solution and the precipitate which forms is collected by filtration. The solid is dried under vacuum to afford 1.059 g (63%) of the desired product. ESI+MS 326 (M+1). Preparation of (S)-4-(1-isothiocyanato-2-(4-nitrophenyl)ethyl)-2-phenylthiazole (4): To a solution of (S)-2-(4-nitrophenyl)-1 -(2-phenylthiazol-4-yl)ethanamine hydrobromide salt, 3, (2.03g, 5 mmol) and CaCO 3 (1 g, 10 mmol) in CCl4/water (10:7.5 mL) is added thiophosgene (0.46 mL, 6 mmol). The reaction is stirred at room temperature for 18 hours then diluted with
CH
2 C1 2 and water. The layers are separated and the aqueous layer extracted with CH 2
CI
2 . The combined organic layers are washed with brine, dried (Na 2
SO
4 ) and concentrated in vacuo to a residue which is purified over silica (CH 2 Cl 2 ) to afford 1.71g (93%) of the desired product. ESI+ MS 368 (M+1). Preparation of (S)-5-methyl-N-(2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethyl)-1,3,4 thiadiazol-2-amine (5): A solution of (S)-4-(1-isothiocyanato-2-(4-nitrophenyl)-ethyl)- 2 phenylthiazole, 4, (332 mg, 0.876 mmol) and acetic hydrazide (65 mg, 0.876 mmol) in EtOH (5 mL) is refluxed for 2 hours. The solvent is removed under reduced pressure, the residue is dissolved in POC1 3 (3 mL) and the resulting solution is stirred at room temperature for 18 hours after which the solution is heated to 50 *C for 2 hours. The solvent is removed in vacuo and the residue is dissolved in EtOAc (40 mL) and the resulting solution is treated with IN NaOH until the pH remains approximately 8. The solution is extracted with EtOAc. The combined aqueous layers are washed with EtOAc, the organic layers combined, washed with brine, dried over MgSO 4 , filtered, and concentrated in vacuo to afford 0.345 g (93%) of the desired product as a yellow solid. 1 H NMR (CDCI 3 ) 8.09 (d, J = 8.4 Hz, 2H), 7.91 (m, 2H), 7.46 (m, 4H), 7.44 (s, I H), 5.23 (m, 1H), 3.59 (m, 2H), 2.49 (s, 3H). ESI+ MS 424 (M+l). Preparation of (S)-4-(2-(5-methyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol- 4 yl)ethyl)phenyls'ulfamic acid (6): (S)-5-Methyl-N-(2-(4-nitrophenyl)-1-(2-phenylthiazol-4 yl)ethyl)-1,3,4-thiadiazol-2-amine, 5, (0.404 g, 0.954 mmol) is dissolved in MeOH (5 mL). Pd/C (50 mg, 10% w/w) is added and the mixture is stirred under a hydrogen atmosphere until the reaction is judged to be complete. The reaction mixture is filtered through a bed of CELITET' and the solvent removed under reduced pressure. The crude product is dissolved in 21 pyridine (4 mL) and treated with S0 3 pyridine (0.304 g, 1.91 mmol). The reaction is stirred at room temperature for 5 minutes after which a 7% solution of NH 4 0H (50 mL) is added. The mixture is then concentrated and the resulting residue is purified by reverse phase preparative HPLC to afford 0.052 g (11% yield) of the desired product as the ammonium salt. '11
(CD
3 OD): 8 8.00-7.97 (m, 2H), 7.51-7.47 (m, 3H), 7.23 (s, IH), 7.11-7.04 (q, 4H, J=9.0 Hz), 5.18 (t, 1H, J=7.2 Hz), 3.34-3.22 (m, 2H), 2.50 (s, 3H). ESI- MS 472 (M-l). The following is a general procedure for isolating the final compound as a free acid. Reduction of the aryl nitro group to free a amine: To a Parr hydrogenation vessel is charged the nitro compound [for example, intermediate 5] (1.0 eq) and Pd/C (10 % Pd on C, 50 % wet, Degussa-type EOI NE/W, 2.68 g, 15 wt %) as solids. MeOH (15 mUg) is added to provide a suspension. The vessel is put on a Parr hydrogenation apparatus. The vessel is submitted to a fill/vacuum evacuate process with N 2 (3 x 20 psi) to inert, followed by the same procedure with H 2 (3 x 40 psi). The vessel is filled with H2 and the vessel is shaken under 40 psi H2 for -40 hr. The vessel is evacuated and the atmosphere is purged with N 2 (5 x 20 psi). An aliquot is filtered and analyzed by HPLC to insure complete conversion. The suspension is filtered through a pad of celite to remove the catalyst, and the homogeneous yellow filtrate is concentrated by rotary evaporation to afford the desired product which is used without further purification. Preparation of free sulfamic acid: A 100 mL RBF is charged with the free amine (1.0 eq) prepared in the step described herein above. Acetonitrile (5 mUg) is added and the yellow suspension which is typically yellow to orange in color is stirred at room temperature. A second 3-necked 500 mL RBF is charged with SO 3 - pyr (1.4 eq) and acetonitrile (5 mUg) and the suspension is stirred at room temperature. Both suspensions are gently heated until the reaction solution containing the amine becomes orange to red-orange in color (typically at about 40-45 *C). This substrate containing solution is poured in one portion into the stirring suspension of
SO
3 - pyr at 35 "C. The resulting opaque mixture is stirred vigorously while allowed to slowly cool to room temperature. After stirring for 45 min, or once the reaction is determined to be complete by HPLC, water (20 mUg) is added to the colored suspension to provide a 22 homogeneous solution having a pH of approximately 2.4. Concentrated H 3 PO4 is added slowly to lower the pH to approximately 1.4. During this pH adjustment, an off-white precipitate typically forms and the solution is stirred at room temperature for an additional hour. The suspension is filtered and the filter cake is washed with the filtrate. The filter cake is air-dried overnight to afford the desired product as the free acid. The following are non-limiting examples of compounds according to the present disclosure. (S)-4-(2-(5-Phenyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl) phenylsulfamic acid: 'H (CD 3 0D): 6 7.97-7.94 (m, 2H), 7.73-7.70 (m, 2H), 7.44-7.39 (m, 6H), 7.25 (s, 1H), 7.12 (s, 4H), 5.29 (t, IH, J=6.9 Hz), 3.35-3.26 (m, 2H). 4.-((S)-2-(5-Propyl-1,3,4-thiadiazol-2-ylamino)-2 -(2-(thiophen-2-yl)thiazol- 4 yl)ethyl)phenylsulfamic acid: 'H (CD 3 OD): 8 7.59-7.54 (i, 2H), 7.17-7.03 (m, 6H), 5.13 (t, 1H, J=7.2 Hz), 3.32-3.13 (m, 2H), 2.81 (t, 2H, J=7.4 Hz), 1.76-1.63 (h, 6H, J=7.4 Hz), 0.97 (t, 3H, J=7.3 Hz). 4-((S)-2-(5-Benzyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4 yl)ethyl)phenylsulfamic acid: 'H (CD 3 OD): S (m, 2H), 7.49-7.45 (m, 2H), 7.26-7.16 (m, 5H), 7.05-6.94 (m, 6H), 5.04 (t, IH, J=7.1 Hz), 4.07 (s, 2H), 3.22-3.04 (m, 2H). 5-(3-Methoxybenzyl)-N-((S)-2-(4-nitrophenyl)-1-(2-(thiophen-2-yl)thiazol-4-yl)ethyl) 1,3,4-thiadiazol-2-amine: 'H (CD 3 0D): 6 7.68-7.64 (m, 2H), 7.33 (t, 1H, J=8.6 Hz), 7.23-7.12 (m, 6H), 6.94-6.91 (m, 3H), 5.22 (t, IH, J=7.1 Hz), 4.22 (s, 2H), 3.86 (s, 3H), 3.40-3.26 (m, 2H). 4-((S)-2-(5-(Naphthalen-1-ylmethyl)-1,3,4-thiadiazol-2-ylaTino)-2-(2-(thiophen-2 yl)thiazol-4-yl)ethyl)phenylsulfamic acid: 'H (CD 3 0D): 6 8.08-8.05 (m, 1H), 7.89-7.80 (m, 2H), 7.55-7.43 (m, 6H), 7.11-7.00 (m, 6H), 5.08 (t, IH, J=7.1 Hz), 4.63 (s, 2H), 3.26-3.08 (m, 2H).
23 4-((S)-2-(5-((Methoxycarbonyl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2 yl)thiazol-4-yl)ethyl)phenylsulfamic acid: 'H(CD 3 0D): 8 7.48-7.44 (m, 2H), 7.03-6.92 (m, 6H), 5.02 (t, 1H, J=7.2 Hz), 4.30 (s, 2H), 3.55 (s, 3H), 3.22-3.02 (m, 2H). 4-((S)-2-(5-((2-Methylthiazol-4-yl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2 yl)thiazol-4-yl)ethyl)phenylsulfamic acid: 'H(CD 3 0D): 5 7.60-7.56 (m, 2H), 7.19 (s, 1 H), 7.15 7.12 (m, 2H), 7.09-7.03 (q, 4H, J=8.7 Hz), 5.14 (t, IH, J=7.2 Hz), 4.28 (s, 2H), 3.33-3.14 (m, 2H), 2.67 (s, 3H). Inhibition of HPTP-P provides a means for enhancing the activity of endothelial receptor tyrosine kinases including, but not limited to, angiopoietin receptor tyrosine kinase, Tie-2, and the VEGF receptor tyrosine kinase, VEGFR2, and thereby treat disease states wherein tissue blood flow is insufficient. The compounds of the present disclosure serve as a means for providing regulation of angiogenesis and other activities of endothelial receptor tyrosine kinases. As such the present disclosure addresses a major unmet medical need, inter alia; Providing compositions of effective human protein tyrosine phosphatase beta (HPTP-Q) inhibitors; and thereby provide a means for regulating angiogenesis, blood vessel remodeling and other activities of endothelial receptor tyrosine kinases in disorders wherein where tissue blood flow is insufficient or where increased blood flow would be beneficial. The effect of human protein tyrosine phosphatase inhibitors has been shown to affect several human disease conditions or disorders, these disorders include, but are not limited to; i) Peripheral Artery Disease - Shiojima, 1. et al., Journal of Clinical Invest., 115, 3108-2118, (2005); ii) Coronary Artery Disease - Siddiqui, A.J. et al., Biochem. Biophys. Res. Comm., 310, 1002-1009, (2003); iii) Myocardial Infarction (Acute Coronary Syndrome) - Takahashi, K. et al., Molecular Therapy, 8, 584-592, (2003); iv) Stroke (Cerebral Vascular Disease) - Stewart, D. et al., Chest, 128, 633-642, (2005); v) Heart Failure - Thurston G., J. Anat., 200, 575-580, (2002); 24 vi) Hypertension - Caravalho, R. S. et al., Bone, 34, 849-861, (2004); vii) Diabetic and Ischemic Neuropathy - Carano, A.D. and Filvaroff, E.H., Drug Discovery Today, 8, 980-989, (2003); viii) Wound Healing and Skin Aging - Simons, M., Circulation, 111, 1556-1566 (2005); xi) Vascular Inflammation and atherosclerosis - Annex, B.H. and Simons M., Cardiovascular Research, 65, 649-655, (2005); x) Vascular Leak Syndromes - Ardelt, A.A. et al., Stroke, 36, 337-341 (2005); and xi) Bone Growth, Maintenance and Repair - Cardiovascular Medicine, 12, 62-66, (2002). FORMULATIONS The present disclosure also relates to compositions or formulations which comprise the HPTPP inhibitors according to the present disclosure. In general, the compositions of the present disclosure comprise: a) an effective amount of one or more phenylsufamic acids and salts thereof according to the present disclosure which are effective as human protein tyrosine phosphatase beta (HPTP-0) inhibitors; and b) one or more excipients. For the purposes of the present disclosure the term "excipient" and "carrier" are used interchangeably throughout the description of the present disclosure and said terms are defined herein as, "ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition." The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach. The formulator can also take advantage of the fact the 25 compounds of the present disclosure have improved cellular potency, pharnacokinetic properties, as well as improved oral bioavailability. Non-limiting examples of compositions according to the present disclosure include: a) from about 0.00 1 mg to about 1000 mg of one or more phenylsulfamic acids according to the present disclosure; and b) one or more excipients. Another embodiment according to the present disclosure relates to the following compositions: a) from about 0.01 mg to about 100 mg of one or more phenylsulfamic acids according to the present disclosure; and b) one or more excipients. A further embodiment according to the present disclosure relates to the following compositions: a) from about 0.1 mg to about 10 mg of one or more phenylsulfamic acids according to the present disclosure; and b) one or more excipients. The term "effective amount" as used herein means "an amount of one or more phenylsulfamic acids, effective at dosages and for periods of time necessary to achieve the desired or therapeutic result." An effective amount may vary according to factors known in the art, such as the disease state, age, sex, and weight of the human or animal being treated. Although particular dosage regimes may be described in examples herein, a person skilled in the art would appreciated that the dosage regime may be altered to provide optimum therapeutic response. Thus, it is not possible to specify an exact "effective amount." For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. In addition, the compositions of the present disclosure can be administered as frequently as necessary to achieve a therapeutic amount. METHOD OF USE The present disclosure relates to methods for regulating angiogenesis in a human comprising administering to a human a compound according to the present disclosure as described herein.
26 One embodiment of the methods of the present disclosure relates to a method for treating a disorder in a subject wherein tissue blood flow reserve is insufficient and chosen from, but not limited to, coronary artery disease, peripheral vascular disease or cerebral vascular disease. A second embodiment of the methods of the present disclosure relates to a method of vascularizing ischemic tissue. As used herein, "ischemic tissue," means tissue that is deprived of adequate blood flow. Examples of ischemic tissue include, but are not limited to, tissue that lack adequate blood supply resulting from myocardial and cerebral infarctions, mesenteric or limb ischemia, or the result of a vascular occlusion or stenosis. In one example, the interruption of the supply of oxygenated blood may be caused by a vascular occlusion. Such vascular occlusion may be caused by arteriosclerosis, trauma, surgical procedures, disease, and/or other etiologies. Also included within the methods of treatment of the present disclosure is the treatment of skeletal muscle and myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, coronary artery disease. A third embodiment of the methods of the present disclosure relates to a method of repairing tissue. As used herein, "repairing tissue" means promoting tissue repair, regeneration, growth, and/or maintenance including, but not limited to, wound repair or tissue engineering. One skilled in the art appreciates that new blood vessel formation is required for tissue repair. In turn, tissue may be damaged by, including, but not limited to, traumatic injuries or conditions including arthritis, osteoporosis and other skeletal disorders, and bums. Tissue may also be damaged by injuries due to surgical procedures, irradiation, laceration, toxic chemicals, viral or bacterial infections, or bums. Tissue in need of repair also includes non-healing wounds. Examples of non-healing wounds include non-healing skin ulcers resulting from diabetic pathology; or fractures that do not heal readily. The compounds of the present disclosure are also suitable for use in effecting tissue repair in the context of guided tissue regeneration (GTR) procedures. Such procedures are currently used by those skilled in the arts to accelerate wound healing following invasive surgical procedures. A fourth embodiment of the methods of the present disclosure relates to a method of promoting tissue repair characterized by enhanced tissue growth during the process of tissue engineering. As used herein, "tissue engineering" is defined as the creation, design, and 27 fabrication of biological prosthetic devices, in combination with synthetic or natural materials, for the augmentation or replacement of body tissues and organs. Thus, the present methods may be used to augment the design and growth of human tissues outside the body for later implantation in the repair or replacement of diseased tissues. For example, antibodies may be useful in promoting the growth of skin graft replacements that are used as a therapy in the treatment of burns. A further iteration of the tissue engineering embodiment of the methods of the present disclosure includes in cell-containing or cell-free devices that induce the regeneration of functional human tissues when implanted at a site that requires regeneration. As discussed herein, biomaterial-guided tissue regeneration may be used to promote bone regrowth in, for example, periodontal disease. Thus, antibodies may be used to promote the growth of reconstituted tissues assembled into three-dimensional configurations at the site of a wound or other tissue in need of such repair. A yet further iteration of the tissue engineering embodiment of the methods of the present disclosure, the compounds described herein may be included in external or internal devices containing human tissues designed to replace the function of diseased internal tissues. This approach involves isolating cells from the body, placing them with structural matrices, and implanting the new system inside the body or using the system outside the body. For example, antibodies may be included in a cell-lined vascular graft to promote the growth of the cells contained in the graft. It is envisioned that the methods of the disclosure may be used to augment tissue repair, regeneration and engineering in products such as cartilage and bone, central nervous system tissues, muscle, liver, and pancreatic islet (insulin-producing) cells. The present disclosure also relates to the use of the phenylsulfamic acids according to the present disclosure in the manufacture of a medicament for promoting the growth of skin graft replacements. The present disclosure also relates to the use of the phenylsulfamic acids according to the present disclosure in the manufacture of a medicament for use in effecting tissue repair in the context of guided tissue regeneration (GTR) procedures. The compounds of the present disclosure can be used in the manufacture of one or more medicaments, non-limiting examples of which are: 28 A compound for use in the manufacture of a medicament useful for the prurposes of tissue engineering thereby affecting enhanced tissue growth. A compound for use in the manufacture of a medicament for the treatment of an ischemic disorder in a subject. PROCEDURES Screening Assays using in vitro and in vivo models of angiogenesis Compounds of the disclosure may be screened in angiogenesis assays that are known in the art. Such assays include in vitro assays that measure surrogates of blood vessel growth in cultured cells or formation of vascular structures from tissue explants and in vivo assays that measure blood vessel growth directly or indirectly (Auerbach,R., et al. (2003). Clin Chem 49, 32-40, Vailhe,B., et al. (2001). Lab Invest 81, 439-452). I. In vitro models of angiogenesis The in vitro models which are suitable for use in the present disclosure employ cultured endothelial cells or tissue explants and measure the effect of agents on "angiogenic" cell responses or on the formation of blood capillary-like structures. Non-limiting examples of in vitro angiogenesis assays include but are not limited to endothelial cell migration and proliferation, capillary tube formation, endothelial sprouting, the aortic ring explant assay and the chick aortic arch assay. 2. In vivo models of angiogenesis The in vivo agents or antibodies which are suitable for use in the present disclosure are administered locally or systemically in the presence or absence of growth factors (i.e. VEGF or angiopoietin 1) and new blood vessel growth is measured by direct observation or by measuring a surrogate marker such as hemoglobin content or a fluorescent indicator. Non-limiting examples of in vitro angiogenesis assays include but are not limited to chick chorioallantoic membrane assay, the corneal angiogenesis assay, and the MATRIGELC plug assay. 3. Procedures for Determining Vascularization of Ischemic Tissue. Standard routine techniques are available to determine if a tissue is at risk of suffering ischemic damage from undesirable vascular occlusion. For example, in myocardial disease these 29 methods include a variety of imaging techniques (e.g., radiotracer methodologies, x-ray, and MRI) and physiological tests. Therefore, induction of angiogenesis as an effective means of preventing or attenuating ischemia in tissues affected by or at risk of being affected by a vascular occlusion can be readily determined. A- person skilled in the art of using standard techniques may measure the vascularization of tissue. Non-limiting examples of measuring vascularization in a subject include SPECT (single photon emission computed tomography); PET (positron emission tomography); MRI (magnetic resonance imaging); and combination thereof, by measuring blood flow to tissue before and after treatment. Angiography may be used as an assessment of macroscopic vascularity. Histologic evaluation may be used to quantify vascularity at the small vessel level. These and other techniques are discussed in Simons, et al., "Clinical trials in coronary angiogenesis," Circulation, 102, 73-86 (2000). The following are non-limiting examples of HPTPp (IC50 pM) and PTP1B (ICso 1 iM) activity is listed herein below in Table 1. TABLE I HPTPP PTPIB Compound ICso PM ICso FIM (S)-4-(2-(5-methyl-1,3,4-thiadiazol-2-ylamino)- 2
-(
2 - 0.003 1.4 phenylthiazol-4-yl)ethyl)phenylsulfamic acid (S)-4-(2-(5-Phenyl-1,3,4-thiadiazol-2-ylamino)-2-( 2 - 0.046 3.7 phenylthiazol-4-yl)ethyl)-phenylsulfamic acid 4-((S)-2-(5-Propyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen- 2 - 0.0002 4.71 yl)thiazol-4-yl)ethyl)phenylsulfamic acid 4-((S)-2-(5-Benzyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2- 0.0006 3.86 yl)thiazol-4-yl)ethyl)phenylsulfamic acid 4-((S)-2-(5-((Methoxycarbonyl)methyl)-1,3,4-thiadiazol-2- 0.002 1.55 ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic 30 acid 4-((S)-2-(5-((2-Methylthiazol-4-yl)methyl)- 1,3,4-thiadiazol-2 0.58 ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenysulfamic 9x1 00 acid The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm." All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. To the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern. While particular embodiments of the present disclosure have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the disclosure. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this disclosure.
31 It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country. In the claims which follow and in the preceding description of the invention, except 5 where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention. 3066226_1 (GHMatters) P80005 AU I 11101/12
Claims (38)
1. A compound having the formula: N R S HO N H Z 5 H wherein R is a unit chosen from; i) hydrogen; ii) substituted or unsubstituted phenyl; and 10 iii) substituted or unsubstituted heteroaryl ring; Z is a substituted or unsubstituted [1,3,4]thiadiazol-2-yl unit having the formula: S (L)x-R' N 15 R' is chosen from: i) hydrogen; ii) substituted or unsubstituted CI-C 6 linear, branched, or cyclic alkyl; iii) substituted or unsubstituted C 6 or Clo aryl; iv) -OR 4 ; 20 v) -C(0)OR'; vi) -COR'; and vii) -NR 7 C(O)OR'; R 4 is hydrogen or substituted or unsubstituted CI-C 6 linear, branched, or cyclic alkyl; R 5 is C 1 C 6 linear or branched alkyl, or benzyl; R 6 is CI-C 6 linear, branched, or cyclic alkyl, or phenyl; 25 R' is hydrogen or methyl; R 8 is CI-C 6 linear or branched alkyl, or benzyl; L is a unit having the formula -[C(R 9 aR 9 b)]y-; R9a and R 9 b are each independently hydrogen, CI-C 6 linear or branched alkyl, or phenyl; and the index x is 0 or 1; the index y is from I to 4. 30 3066226_1 (GHMatters) P80005.AU.1 11101112 33
2. A compound according to Claim I wherein R is phenyl.
3. A compound according to Claim I wherein R is a heteroaryl unit chosen from 1,2,3,4 tetrazol-l-yl ,1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [I,2,3]triazol-5-yl, [I,2,4]triazol-4-yl, 5 [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4 yl., oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yi, [l,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene 3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [I,2,4]thiadiazol-3-yl, [l,2,4]thiadiazol-5-yi, and [1,3,4]thiadiazol-2-yl. 10
4. A compound according to Claim 3 wherein R is thiophene-2-yl or thiophene-3-yi.
5. A compound according to Claim I wherein R' is chosen from methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and i5 cyclopropylmethyl.
6. A compound according to Claim I wherein L has the formula -CH 2 -.
7. A compound according to Claim 6 wherein R' is chosen from substituted or 20 unsubstituted phenyl, naphthalen-I-yl, and thiazol-4-yl, said substitutions chosen from methyl, ethyl, n-propyl, hydroxy, hydroxymethyl, methoxy, fluoro, chloro, and trifluoromethyl.
8. A compound according to Claim 7 wherein R' is chosen from phenyl, naphthalen-l yl, 3-methoxyphenyl, and 2-methylthiazol-4-yl. 25
9. A compound chosen from: (S)-{4-[2-(5-methyl-[ 1,3,4]th iad iazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl} sulfamic acid; (S)-4-(2-(5-Phenyl- 1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl)-phenylsulfamic 30 acid; 4-((S)-2-(5-Propyl-l,3,4-th iadiazol-2-ylam ino)-2-(2-(thiophen-2-yl)thiazol-4 yl)ethyl)phenylsulfamic acid; 4-((S)-2-(5-Benzyl- 1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4 yl)ethyl)phenylsulfamic acid; 35 5-(3-Methoxybenzyl)-N-((S)-2-(4-nitrophenyl)-l-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)-1,3,4 th iad iazol-2-amine; 4-((S)-2-(5-(Naphthalen- I -ylmethyl)-1,3,4-th iadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4 3066226_ I (GHMatters)P80005 AU.1 11/01112 34 yl)ethyl)phenylsulfamic acid; 4-((S)-2-(5-((Methoxycarbonyl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2 yl)thiazol-4-yl)ethyl)phenylsulfamic acid; and 4-((S)-2-(5-((2-Methylth iazol-4-yI)methyl)-I,3,4-thiadiazol-2-ylamino)-2-(2-(th iophen-2 5 yl)thiazol-4-yl)ethyl)phenylsulfamic acid.
10. A composition comprising: A) one or more compounds according to Claim I ; and B) one or more excipients or carriers. 10 1. The use of a compound according to any of Claims 1-10 and 16-18, for treating a condition chosen from skeletal muscle and myocardial ischemia, stroke, peripheral vascular disease and coronary artery disease. i5 12. The use of a compound according to any of Claims 1-10 and 16-18, for treating angiogenesis.
13. The use of a compound according to any of Claims 1-10 and 16-18, for vascularizing ischemic tissue. 20
14. The use of a compound according to any of Claims 1-10 and 16-18, for promoting the growth of skin graft replacements.
15. The use of a compound according to any of Claims 1-10 and 16- 18, for promoting 25 tissue repair in the context of guided tissue regeneration (GTR) procedures.
16. A method for treating a disease chosen from a disorder chosen from skeletal muscle and myocardial ischemia, stroke, peripheral vascular disease and coronary artery disease comprising administering to a human a compound according to Claim 1. 30
17. A method for regulating angiogenesis in a human comprising administering to a human a compound according to Claim 1.
18. A method for vascularizing ischemic tissue in a human comprising administering to a 35 human a compound according to Claim 1. 30662261 (GHMatters) P80O05.AU.I 11/01/12 35
19. A method for promoting the growth of skin graft replacements comprising administering to a human a compound according to Claim 1.
20. A method for promoting tissue repair in the context of guided tissue regeneration 5 (GTR) procedures comprising administering to a human a compound according to Claim 1.
21. A compound according to Claim 1, wherein the compound is a pharmaceutically acceptable salts of either basic groups or acid groups. 10 22. A compound according to Claim 21, wherein the compounds are salts comprising anions chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate. 15 23. A compound according to Claim 21, wherein the compounds are salts comprising cations chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
24. The use of a compound according to any of Claims 1-10 and 21-23, for making a medicament for treating a condition chosen from skeletal muscle and myocardial ischemia, 20 stroke, peripheral vascular disease and coronary artery disease.
25. The use of a compound according to any of Claims 1-10 and 21-23, for making a medicament for treating angiogenesis. 25 26. The use of a compound according to any of Claims 1-10 and 21-23, for making a medicament for vascularizing ischemic tissue.
27. The use of a compound according to any of Claims 1-10 and 21-23, for making a medicament for promoting the growth of skin graft replacements. 30
28. The use of a compound according to any of Claims 1-10 and 21-23, for making a medicament for promoting tissue repair in the context of guided tissue regeneration (GTR) procedures. 35 29. The use of a compound according to any of Claims 1-10 and 21-23, for use as a medicament. 3066226_1 (GHMatte) P800O5.AU I 11/01/12 36
30. A compound having the formula: S / R N HO' N H Z H wherein R is a unit chosen from: i) hydrogen; 5 ii) substituted or unsubstituted phenyl; and iii) substituted or unsubstituted heteroaryl ring; Z is a substituted or unsubstituted [1,3,4]thiadiazol-2-yl unit having the formula: S (L)x-R' N 10 R1 is chosen from: i) hydrogen; ii) substituted or unsubstituted CI-C 6 linear, branched, or cyclic alkyl; iii) substituted or unsubstituted C 6 or CIO aryl; iv) -OR 4 ; 15 v) -C(O)OR'; vi) -COR 6 ; and vii) -NR'C(O)OR'; R 4 is hydrogen or substituted or unsubstituted Ci-C 6 linear, branched, or cyclic alkyl; R' is C 1 C 6 linear or branched alkyl, or benzyl; R 6 is Ci-C 6 linear, branched, or cyclic alkyl, or phenyl; 20 R7 is hydrogen or methyl; R8 is CI-C 6 linear or branched alkyl, or benzyl; L is a unit having the formula -[C(R"aR 9 b)]y_ 9b9 R 9 ' and R9b are each independently hydrogen, CI-C 6 linear or branched alkyl, or phenyl; and the index x is 0 or 1; the index y is from I to 4; or a pharmaceutically acceptable salt thereof. 25
31. A compound according to Claim 30, wherein R is phenyl.
32. A compound according to Claim 30 wherein R is a heteroaryl unit chosen from 1,2,3,4-tetrazol- 1 -yl, 1,2,3,4-tetrazol-5-yl, [I ,2,3]triazol-4-yl, [ 1,2,3]triazol-5-yl, [1,2,4]triazol 4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, 30 oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [l,2,4]oxadiazol-3-yl, [l ,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yi, thiophene 3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, 3066226_1 (GHMtters) P80005 AU I 11/01/12 37 [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, and [1,3,4]thiadiazol-2-yl.
33. A compound according to Claim 32, wherein R is thiophene-2-yl or thiophene-3-yl. s 34. A compound according to Claim 30, wherein R' is chosen from methyl, ethyl, n propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and cyclopropylmethyl.
35. A compound according to Claim 30, wherein L has the formula -CH 2 -. 10 36. A compound according to Claim 35, wherein R' is chosen from substituted or unsubstituted phenyl, naphthalen-l-yl, and thiazol-4-yl, said substitutions chosen from methyl, ethyl, n-propyl, hydroxy, hydroxymethyl, methoxy, fluoro, chloro, and trifluoromethyl.
37. A compound according to Claim 36, wherein R' is chosen from phenyl, naphthalen-I 15 yl, 3-methoxyphenyl, and 2-methylthiazol-4-yl.
38. A compound according to Claim 30, chosen from: (S)-4-(2-(5-Phenyl- 1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl)-phenylsulfamic acid; 20 4-((S)-2-(5-Propyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4 yl)ethyl)phenylsulfamic acid; 4-((S)-2-(5-Benzyl- 1,3,4-thiadiazol-2-ylanino)-2-(2-(thiophen-2-yl)thiazol-4 yl)ethyl)phenylsulfamic acid; 5-(3-Methoxybenzyl)-N-((S)-2-(4-nitrophenyl)-I -(2-(thiophen-2-yl)thiazol-4-yl)ethyl)-1,3,4 25 thiadiazol-2-amine; 4-((S)-2-(5-(Naphthalen- I -ylmethyl)- 1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4 yl)ethyl)phenylsulfamic acid; 4-((S)-2-(5-((Methoxycarbonyl)methyl)- 1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2 yl)thiazol-4-yl)ethyl)phenylsulfamic acid; and 30 4-((S)-2-(5-((2-Methylthiazol-4-yl)methyl)- 1,3,4-thiadiazol-2-ylam ino)-2-(2-(thiophen-2 yl)thiazol-4-yl)ethyl)phenylsulfamic acid.
39. A compound according to any of Claims 30-38, wherein the compounds are salts comprising anions chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, 35 bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate. 3066226_1 (GHMauers) P0005.AU. 111/01/12 38
40. A compound according to any of Claims 30-38, wherein the compounds are salts comprising cations chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
41. A composition comprising: 5 A) one or more compounds according to any of Claims 30-38; and B) one or more excipients or carriers.
42. The use of a compound according to any of Claims 30-38 or a composition of Claim 41, for making a medicament for treating a condition chosen from skeletal muscle and 10 myocardial ischemia, stroke, peripheral vascular disease and coronary artery disease.
43. The use of a compound according to any of Claims 30-38 or a composition of Claim 41, for making a medicament for treating angiogenesis. 15 44. The use of a compound according to any of Claims 30-38 or a composition of Claim 41, for making a medicament for vascularizing ischemic tissue.
45. The use of a compound according to any of Claims 30-38 or a composition of Claim 41, for making a medicament for promoting the growth of skin graft replacements. 20
46. The use of a compound according to any of Claims 30-38 or a composition of Claim 41, for making a medicament for promoting tissue repair in the context of guided tissue regeneration (GTR) procedures. 25 47. The use of a compound according to any of Claims 30-38 or a composition of Claim 41, for use as a medicament.
48. Compounds according to any of Claims 30-38 or a composition containing them or methods or uses involving them substantially as herein described with reference to the 30 accompanying examples. 3066226_1 (GHMatters) PO0OS.AU. 11/01112
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012200253A AU2012200253B2 (en) | 2006-06-27 | 2012-01-16 | Human protein tyrosine phosphatase inhibitors and methods of use |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/816,825 | 2006-06-27 | ||
AU2007265455A AU2007265455B2 (en) | 2006-06-27 | 2007-06-27 | Human protein tyrosine phosphatase inhibitors and methods of use |
AU2012200253A AU2012200253B2 (en) | 2006-06-27 | 2012-01-16 | Human protein tyrosine phosphatase inhibitors and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007265455A Division AU2007265455B2 (en) | 2006-06-27 | 2007-06-27 | Human protein tyrosine phosphatase inhibitors and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2012200253A1 true AU2012200253A1 (en) | 2012-02-16 |
AU2012200253B2 AU2012200253B2 (en) | 2012-07-05 |
Family
ID=45812216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012200253A Ceased AU2012200253B2 (en) | 2006-06-27 | 2012-01-16 | Human protein tyrosine phosphatase inhibitors and methods of use |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2012200253B2 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050154011A1 (en) * | 2003-02-20 | 2005-07-14 | The Procter & Gamble Company | Tetrahydroisoquinolnyl sulfamic acids |
-
2012
- 2012-01-16 AU AU2012200253A patent/AU2012200253B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2012200253B2 (en) | 2012-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007265455B2 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
ES2534392T3 (en) | Human tyrosine phosphatase protein inhibitors and methods of use | |
JP2009542659A5 (en) | ||
AU2012200253B2 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
RU2435763C2 (en) | Human protein tyrosine phosphatase inhibitors and application methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
PC | Assignment registered |
Owner name: AERPIO THERAPEUTICS, INC. Free format text: FORMER OWNER WAS: WARNER CHILCOTT, LLC |
|
PC | Assignment registered |
Owner name: AERPIO PHARMACEUTICALS, INC. Free format text: FORMER OWNER(S): AERPIO THERAPEUTICS, INC. |
|
PC | Assignment registered |
Owner name: EYEPOINT PHARMACEUTICALS, INC. Free format text: FORMER OWNER(S): AERPIO PHARMACEUTICALS, INC. |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |